Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PBRM1 | Q86U86 | 13/20 | 0.36 |
| ▸ | SMARCA2 | P51531 | 12/20 | 0.36 |
| ▸ | SMARCA4 | P51532 | 12/20 | 0.36 |
| ▸ | IKBKB | O14920 | 4/20 | 0.34 |
| ▸ | CHUK | O15111 | 1/20 | 0.34 |
| ▸ | NR1I2 | O75469 | 8/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.32 |
| ▸ | CASP3 | P42574 | 1/20 | 0.32 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.32 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.32 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.32 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26653968 | 0.83 | IKBKB (0.39) | PBRM1SMARCA2SMARCA4IKBKBCHUK | |
| SCHEMBL26654141 | 0.83 | IKBKB (0.39) | PBRM1SMARCA2SMARCA4IKBKBCHUK | |
| SCHEMBL26654149 | 0.83 | IKBKB (0.39) | PBRM1SMARCA2SMARCA4IKBKBCHUK | |
| SCHEMBL26653822 | 0.81 | PDE10A (0.42) | PBRM1SMARCA2SMARCA4IKBKBCHUK | |
| SCHEMBL26654239 | 0.80 | PBRM1 (0.42) | PBRM1SMARCA2SMARCA4IKBKBCHUK | |
| SCHEMBL26804404 | 0.78 | PBRM1 (0.41) | PBRM1SMARCA2SMARCA4IKBKBCHUK | |
| SCHEMBL30658035 | 0.78 | SMARCA2 (0.47) | PBRM1SMARCA2SMARCA4NR1I2 | |
| SCHEMBL26653853 | 0.78 | SMARCA2 (0.47) | PBRM1SMARCA2SMARCA4NR1I2 | |
| SCHEMBL26654139 | 0.78 | PBRM1 (0.37) | PBRM1SMARCA2SMARCA4IKBKBCHUK | |
| SCHEMBL30658001 | 0.75 | PBRM1 (0.34) | PBRM1SMARCA2SMARCA4IKBKBCHUK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250302832-A1 | PYRAZINE DERIVATIVES AND USES THEREOF | FOGHORN THERAPEUTICS INC (US) | 2025-10-02 | — | — | US | disclosed |
| CN-120035593-A | Pyrazine derivatives and uses thereof | 福宏治疗公司 | 2025-05-23 | — | — | CN | disclosed |
| EP-4522279-A1 | PYRAZINE DERIVATIVES AND USES THEREOF | Foghorn Therapeutics Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| WO-2023220134-A1 | PYRAZINE DERIVATIVES AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023220134-A1 | PYRAZINE DERIVATIVES AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2023-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250302832-A1 | PYRAZINE DERIVATIVES AND USES THEREOF | BRCA1, VHL, SF3B5 | PBRM1 7/4885SMARCA2 77/4885SMARCA4 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.